Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02164422 · ClinicalTrials.gov registry record · Phase 2
Does Guanfacine Attenuate Stress-Induced Drinking?
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT02164422 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 70 participants.
The verdict
NCT02164422, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
Evaluating the effect of guanfacine on alcohol consumption. The investigators hypothesize that guanfacine versus placebo will decrease the amount of alcohol consumption (mls consumed) during the 2-hour self-administration period across two laboratory sessions.
Interventions
- DRUG Placebo
- DRUG Guanfacine 3mg/day
- DRUG Guanfacine 1.5mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2014-06 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02164422
The ClinicalTrials.gov registry entry for NCT02164422 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02164422 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02164422 about?
NCT02164422 is a clinical study titled "Does Guanfacine Attenuate Stress-Induced Drinking?". Evaluating the effect of guanfacine on alcohol consumption. The investigators hypothesize that guanfacine versus placebo will decrease the amount of alcohol consumption (mls consumed) during the 2-hour self-administration period across two laboratory sessions.
What is the current status of trial NCT02164422?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2014-06. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT02164422?
The interventions under investigation include: Placebo (DRUG), Guanfacine 3mg/day (DRUG), Guanfacine 1.5mg/day (DRUG).
Who is sponsoring clinical trial NCT02164422?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.